Treatment of Cancer with LGR5/EGFR Antibody and Topoisomerase I Inhibitor

The EPO published Merus B.V.'s patent application EP4017879A2 covering cancer treatment using a combination of an anti-LGR5/EGFR antibody with a topoisomerase I inhibitor. The application details therapeutic compositions, methods of treatment, and synergistic effects of the combination therapy. Applicants include Merus B.V. with inventors Throsby and Wasserman.

This is a patent publication rather than a regulatory requirement. Pharmaceutical companies developing similar antibody-drug conjugate or cancer combination therapies should review this patent for potential freedom-to-operate implications. The patent designates all EU member states plus other European countries. No immediate compliance actions are required, but companies should monitor the prosecution of this application for claim scope that may affect their product development.